All Stories

  1. Clinical, Endoscopic, and Histological Characteristics of Severe Immune Checkpoint Inhibitor-Induced Colitis

    Article • Journal of Clinical Medicine, January 2026, MDPI AG

    Eduard Brunet

  2. Systemic Consequences of Inflammatory Bowel Disease Beyond Immune-Mediated Manifestations

    Article • Journal of Clinical Medicine, November 2025, MDPI AG

    Eduard Brunet

  3. Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn’s disease who no longer respond to the drug when administered subcutaneously

    Article • Therapeutic Advances in Gastroenterology, July 2025, SAGE Publications

    Eduard Brunet

  4. Cribado de displasia en pacientes con enfermedad inflamatoria intestinal: a quién, cuándo y cómo

    Article • Gastroenterología y Hepatología, June 2025, Elsevier

    Eduard Brunet

  5. Desvelando la conexión intestino-grasa-inflamación en la enfermedad de Crohn: ¿hacia nuevos objetivos terapéuticos?

    Article • Gastroenterología y Hepatología, May 2025, Elsevier

    Eduard Brunet

  6. Global evolution of inflammatory bowel disease across epidemiologic stages

    Article • Nature, April 2025, Springer Science + Business Media

    Eduard Brunet

  7. Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU

    Article • Journal of Crohn s and Colitis, April 2025, Oxford University Press (OUP)

    Eduard Brunet

  8. Utilidad de la cápsula endoscópica de intestino delgado en los pacientes con enfermedad de Crohn

    Article • Gastroenterología y Hepatología, March 2025, Elsevier

    Eduard Brunet

  9. Asymptomatic Inflammatory Bowel Disease Diagnosed During Colorectal Cancer Population Screening in Catalonia: Characteristics and Natural History

    Article • Clinical and Translational Gastroenterology, December 2024, Wolters Kluwer Health

    Eduard Brunet

  10. Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence

    Article • The American Journal of Gastroenterology, November 2024, Wolters Kluwer Health

    MD. PhD. Carlos Taxonera, Eduard Brunet

  11. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Article • Digestive and Liver Disease, November 2024, Elsevier

    Eduard Brunet

  12. Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry

    Article • Journal of Crohn s and Colitis, August 2024, Oxford University Press (OUP)

    Eduard Brunet

  13. Gene content, phage cycle regulation model and prophage inactivation disclosed by prophage genomics in the Helicobacter pylori Genome Project

    Article • Gut Microbes, August 2024, Taylor & Francis

    Dr. Roberto Herrera-Goepfert, Khaled Jadallah, Eduard Brunet

  14. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Article • Alimentary Pharmacology & Therapeutics, June 2024, Wiley

    Eduard Brunet

  15. Commentary on the Epidemiology of Inflammatory Bowel Disease in Compounding Prevalence Nations: Toward Sustaining Healthcare Delivery

    Article • Gastroenterology, June 2024, Elsevier

    Eduard Brunet

  16. Ischemic colitis due to Kayexalate crystals

    Article • Gastroenterología y Hepatología (English Edition), April 2024, Elsevier

    Eduard Brunet

  17. The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation: EITOS Study of GETECCU

    Article • Inflammatory Bowel Diseases, March 2024, Oxford University Press (OUP)

    Eduard Brunet

  18. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Article • Therapeutic Advances in Gastroenterology, January 2024, SAGE Publications

    MD. PhD. Carlos Taxonera, Eduard Brunet

  19. Cyclosporine treatment for severe steroid refractory immune-mediated colitis in a patient with ulcerative colitis

    Article • Gastroenterología y Hepatología, January 2024, Elsevier

    Eduard Brunet

  20. Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis

    Article • Therapeutic Advances in Gastroenterology, January 2024, SAGE Publications

    Eduard Brunet

  21. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Article • Therapeutic Advances in Gastroenterology, January 2024, SAGE Publications

    Eduard Brunet

  22. The Helicobacter pylori Genome Project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes

    Article • Nature Communications, December 2023, Springer Science + Business Media

    Dr. Roberto Herrera-Goepfert, Dr Ben Pascoe, Khaled Jadallah, Eduard Brunet

  23. Incidence of Myelotoxicity and Other Adverse Effects Related to Thiopurine Starting in Patients with Inflammatory Bowel Disease: Retrospective Observational Study in a Third-Level Hospital

    Article • Journal of Clinical Medicine, October 2023, MDPI AG

    Eduard Brunet

  24. Development and validation of the inflammatory bowel disease objective disability index (IBDODI)

    Article • July 2023, Cold Spring Harbor Laboratory Press

    Eduard Brunet

  25. Endoscopic treatment (endoscopic balloon dilation/self-expandable metal stent) vs surgical resection for the treatment of de novo stenosis in Crohn’s disease (ENDOCIR study): an open-label, multicentre, randomized trial

    Article • Trials, June 2023, Springer Science + Business Media

    Eduard Brunet

  26. Significant Differences in IBD Care and Education across Europe: Results of the Pan-European VIPER Survey

    Article • Digestive Diseases, November 2022, Karger Publishers

    Eduard Brunet

  27. Heterogeneity in pharmacological treatment and outcomes in Crohn’s disease patients in Catalonia: a population-based observational study

    Article • Annals of Medicine, May 2022, Taylor & Francis

    Eduard Brunet

  28. Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study

    Article • Alimentary Pharmacology & Therapeutics, February 2022, Wiley

    Eduard Brunet

  29. Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients

    Article • Journal of Clinical Medicine, February 2022, MDPI AG

    Eduard Brunet

  30. Ileitis as the exclusive manifestation of COVID-19. The first reported case

    Article • Gastroenterología y Hepatología, October 2021, Elsevier

    Eduard Brunet

  31. Time Trends of Crohn’s Disease in Catalonia from 2011 to 2017. Increasing Use of Biologics Correlates with a Reduced Need for Surgery

    Article • Journal of Clinical Medicine, September 2020, MDPI AG

    Eduard Brunet

  32. Revisión del manejo del síndrome diarreico después de una cirugía bariátrica

    Article • Endocrinología Diabetes y Nutrición, June 2020, Elsevier

    Eduard Brunet

  33. Review of the management of diarrhea syndrome after bariatric surgery

    Article • Endocrinología Diabetes y Nutrición (English ed ), June 2020, Elsevier

    Eduard Brunet

  34. Análisis de los índices predictores de respuesta al tratamiento con ácido ursodeoxicólico en pacientes con colangitis biliar primaria

    Article • Medicina Clínica, May 2019, Elsevier

    Eduard Brunet

  35. Púrpura trombocitopénica inmune asociada a enfermedad de Crohn con respuesta completa a infliximab

    Article • Gastroenterología y Hepatología, January 2019, Elsevier

    Eduard Brunet

  36. A study of the prevalence, incidence and mortality of inflammatory bowel disease in Catalonia

    Article • Annals of Medicine, September 2018, Taylor & Francis

    Xavier Calvet, Eduard Brunet